A combination of pills that cures 9 of 10 hepatitis C patients and is well tolerated by patients, reveals a new study.

Lead researcher, Eric Lawitz, said that they were now in the midst of a paradigm shift of moving away from complicated injection regimens that included interferon and often caused significant side effects with modest success rates.
Lawitz added that this trial provided a glimpse into the outcomes of sofosbuvir and simeprevir for treatment of hepatitis C and both drugs were approved by the FDA but were not yet approved together for this treatment.
This study is published in The Lancet.
Source-ANI